DeepTrace Technologies's Product Videos
Compete with DeepTrace Technologies?
Ensure that your company and products are accurately represented on our platform.
DeepTrace Technologies's Products & Differentiators
TRACE4AD is a medical device that provides the subject's level of risk (low or high risk) of having or progressing to Alzheimer's disease (AD) dementia within 24 months, by an automatic reading of the subject's brain study obtained from a 3D structural T1-weighted MRI brain study of the duration of 10 minutes, also in combination with a neuropsychological assessment of the subject. TRACE4AD is CE-marked for cloud and on-premise use and has 83% sensitivity and 87% specificity.
Expert Collections containing DeepTrace Technologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
DeepTrace Technologies is included in 3 Expert Collections, including Artificial Intelligence.
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Startups recreating how healthcare is delivered
DeepTrace Technologies Patents
DeepTrace Technologies has filed 1 patent.
Latest DeepTrace Technologies News
Jan 14, 2021
DeepTrace Technologies is an innovative startup, a spin-off of the Istituto Universitario di Studi Superiori (Iuss of Pavia), which operates in the field of artificial intelligence, combining it with medical imaging in order to make diagnoses and prognoses in a more accurate, faster and predictive way. Thus saving time which, in certain circumstances and conditions, can be extremely precious. The Progress Tech Transfer fund launched last year by Mito Technology has subscribed the first round of investment for $2 million (€1.7 million), acquiring a minority share, assisted by Klecha & Co as financial advisor. If you want to find more details about the startup DeepTrace Technologies and its latest developments, download for free the Born2Invest mobile app. Our companion app brings you the most important business headlines in the world, so you can stay on top of the market. Born2Invest is available for both Android and iOS devices. But what does DeepTrace do? Founded in 2018, but based on research work rooted at least in 2015, the startup has developed a radiological image analysis system based on the use of AI that improves the speed of screening, the quality of diagnosis and allows to modulate the most suitable therapy for the patient. A solution that integrates the work of medical specialists and specialized technicians and makes it possible to predict the risk of the onset of the disease, its evolution and the possible poor response to a given therapy, thus reducing consequent healthcare costs and avoiding invasive medical tests, ineffective treatments and unnecessary care. “The company’s approach, based on data analytics and personalized predictive medicine, enables the delivery of highly efficient, low-cost and limited-risk medical devices,” reads a note from Klecha, a private pan-European investment bank specializing in the technology, software, IT services, hardware and IoT sectors. “In less than three years, DeepTrace Technologies has developed more than 10 predictive models for various diseases, including Alzheimer’s, for different types of carcinoma and for viral diseases including, most recently, Covid-19. The model for Covid-19 interstitial pneumonia The company has in fact developed last spring, and in a few weeks thanks to the collaboration with a group of clinical researchers from the University of Milan Bicocca, the State University of Milan, CNR, IRCCS Policlinico San Donato and San Gerardo Hospital in Monza, a method to recognize the presence of interstitial pneumonia caused by coronavirus on the basis of a normal digital X-ray of the patient. A method developed by training the proprietary platform Trace4 to identify and recognize the features that differentiate the radiographic images of the lungs of individuals affected by Covid-19 from those with similar symptoms. The advantages lie in the rapidity of response, low cost and maximum versatility, as in other types of diseases. The company aims to obtain European certification for its devices The investment round will allow the startup, led by CEO Christian Salvatore, to obtain CE certification for its proprietary medical devices and expand the spectrum of diseases covered by the application. Not only that: a part of the resources will be dedicated to the improvement of the analysis software with the aim of making it even more complete and customizable, allowing customers to take advantage of it as much as possible. __ DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures . First published in Smartmoney , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
DeepTrace Technologies Web Traffic
DeepTrace Technologies Rank
DeepTrace Technologies Frequently Asked Questions (FAQ)
When was DeepTrace Technologies founded?
DeepTrace Technologies was founded in 2018.
Where is DeepTrace Technologies's headquarters?
DeepTrace Technologies's headquarters is located at Via Conservatorio 17, Milan.
What is DeepTrace Technologies's latest funding round?
DeepTrace Technologies's latest funding round is Corporate Minority.
How much did DeepTrace Technologies raise?
DeepTrace Technologies raised a total of $2.07M.
Who are the investors of DeepTrace Technologies?
Investors of DeepTrace Technologies include MITO Technology and Istituto Universitario di Studi Superiori.
Who are DeepTrace Technologies's competitors?
Competitors of DeepTrace Technologies include QUIBIM and 3 more.
What products does DeepTrace Technologies offer?
DeepTrace Technologies's products include TRACE4AD and 2 more.
Compare DeepTrace Technologies to Competitors
Ultromics provides autonomous echocardiography analysis through AI solutions, empowering physicians to make decisions when diagnosing cardiovascular disease. Its cloud-based service, EchoGo, uses artificial intelligence to fully automate the pathway to diagnosis, providing reports for clinicians without any need for physical software on-site. The company was founded in 2017 and is based in Oxford, U.K.
AMRA Medical provides a cloud-based, computer-aided service, AMRA Profiler, which translates data from a 6-minute whole body MRI scan into fat and muscle measurements in such areas as obesity, NAFLD / NASH, cardiovascular disease, diabetes, oncology, sarcopenia, cachexia, muscle disorders, rare diseases, etc.
Infervision is a global high-tech enterprise in medical artificial intelligence, aiming to empower doctors with higher efficiency and benefit patients with better diagnosis, outcome, and lower cost. Infervision provides products and services to providers, and patients; with robust A.I. solutions fully integrated with the healthcare workflow to help diagnosing various diseases and conditions such as cerebral hemorrhage, lung cancer, bone fractures, emphysema, and more. Infervision also provides an AI-powered research platform for medical professionals with any research directions and needs.
mediaire offers (neuro)radiologists a detailed brain volumetry and lesion report for each patient by an automated, AI-based MRI analysis within just five minutes locally in their center. The radiologist can therefore talk through the MR report within the same patient appointment. Its first product family with mdbrain & mdspine is already certified as a medical device in Europe according to DIN EN ISO 13485:2016.
Koios Medical is a provider of software solutions for radiologists diagnosing cancer. Using AI algorithms trained on thousands of images combined with data from pathology results, Koios DS™ is decision support for healthcare diagnostics. Koios Medical was formerly known as Clearview Diagnostics. The company was founded in 2012 and is based in Chicago, Illinois.
Qure.ai provides an artificial intelligence-based system to identify abnormalities in head CT scans. It leverages deep learning effectively to diagnose diseases from radiology and pathology imaging and create personalized cancer treatment plans from psychopathology imaging and genome sequences. It was founded in 2016 and is based in Mumbai, India.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.